Quantum Biopharma (NASDAQ:QNTM) Upgraded by Wall Street Zen to Hold Rating

Quantum Biopharma (NASDAQ:QNTM) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Quantum Biopharma in a report on Monday, December 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Quantum Biopharma currently has an average rating of “Sell”.

Quantum Biopharma Stock Performance

QNTM stock opened at $8.89 on Friday. The company has a fifty day moving average price of $10.33 and a 200-day moving average price of $16.46. The company has a market capitalization of $33.96 million, a P/E ratio of -0.82 and a beta of 0.15. Quantum Biopharma has a 52-week low of $2.70 and a 52-week high of $38.25.

Quantum Biopharma (NASDAQ:QNTM) last issued its quarterly earnings data on Friday, November 7th. The company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($1.05). As a group, sell-side analysts forecast that Quantum Biopharma will post -3.27 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Quantum Biopharma

A hedge fund recently bought a new stake in Quantum Biopharma stock. Steward Partners Investment Advisory LLC acquired a new position in shares of Quantum Biopharma Ltd. (NASDAQ:QNTM) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 3,100 shares of the company’s stock, valued at approximately $63,000. Steward Partners Investment Advisory LLC owned approximately 0.11% of Quantum Biopharma at the end of the most recent reporting period. Institutional investors and hedge funds own 1.24% of the company’s stock.

About Quantum Biopharma

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.